AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02301286
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001300
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03091075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group will receive placebo for 12 weeks postoperative
Trial: NCT00711607
Drug: nomegestrol acetate and estradiol
RxNorm normalized name: nomegestrol and estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
Trial: NCT04016246
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
Trial: NCT00030420
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
Trial: NCT04167995
Drug: Probiotic Formula lacteal forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
Trial: NCT03444298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose consists of two capsules by mouth once daily for a total of 7 days.
Trial: NCT02942771
Drug: 0.075mg/kg TT301/MW189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg/kg IV twice daily on Days 1 through 5
Trial: NCT02942771
Drug: 0.30mg/kg TT301/MW189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg/kg IV twice daily on Days 1 through 5
Trial: NCT02942771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride
Trial: NCT00085098
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV over 1 hour
Trial: NCT01962545
Drug: OAC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single APT with either aspirin or clopidogrel is discontinued in this arm.
Trial: NCT04499105
Drug: Mesenchymal Stem Cell + NaCl 0,9% 2ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.
Trial: NCT01153620
Drug: Lavasept 0.04%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes
Trial: NCT01949103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005808
Drug: photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo laser therapy
Trial: NCT03835013
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.9% saline
Trial: NCT01028261
Drug: ZGN-433
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
Trial: NCT01496170
Drug: MK-8931
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
Trial: NCT00003086
Drug: CAF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003086
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003086
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003086
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00868699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT01496170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, orally, once per day for 7 days
Trial: NCT01929707
Drug: LY3050258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01929707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00106639
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg twice daily
Trial: NCT00106639
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg twice daily
Trial: NCT03380507
Drug: Triple therapy group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refer to arms description
Trial: NCT02423707
Drug: ALK Alutard Birch and/or 5-grasses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use.
Trial: NCT01054118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension and placebo capsule administered as single doses
Trial: NCT03517618
Drug: S-1+leucovorin
RxNorm normalized name: (S)-Leucovorin
DrugBank: (6R)-Folinic acid (DB03256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study.
Trial: NCT00424502
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25mg po/week
Trial: NCT01159600
Drug: Placebo identical to BI 10773 low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching BI 10773 low dose
Trial: NCT01159600
Drug: Placebo identical to BI 10773 high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching BI 10773 high dose
Trial: NCT04536961
Drug: Reference Treatment- BMS-986165-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT01047722
Drug: Aspirin ingestion followed by doing a Bleeding Volume Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
Trial: NCT01811459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO or IV
Trial: NCT05248724
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of 0.9 saline
Trial: NCT00553488
Drug: Regular insulin (Humulin)
RxNorm normalized name: insulin isophane / insulin, regular, human Pen Injector [Humulin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
Trial: NCT04062123
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
Trial: NCT04062123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid IV solution will be infused, with no active drug.
Trial: NCT00483704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT01526590
Drug: Definity Contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
Trial: NCT04164823
Drug: Analgesic self-medication (OTC)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
Trial: NCT01706575
Drug: Nucleos(t)ide Analogues (NA)
RxNorm normalized name: levothyroxine sodium Oral Tablet [Levo-T]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
Trial: NCT00227500
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00819078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no dosage
Trial: NCT02454556
Drug: FOLITIME®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02454556
Drug: Gonal-F®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00236275
Drug: Fluoro-L-thymidine-(18F)
RxNorm normalized name: L-thymidine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fluoro-L-thymidine-(18F)
Trial: NCT00925652
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00925652
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00785798
Drug: Pegylated Liposomal Doxorubicin (PLD), Doxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 30mg/m2 on day 3 of a 21-day cycle
Trial: NCT01599078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
Trial: NCT00003754
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00093847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be taken daily for 6 weeks
Trial: NCT04624776
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
Trial: NCT02795520
Drug: OTS167IV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00283920
Drug: [(11)C] PBR28
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00484198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
Trial: NCT03090698
Drug: Hylan G-F 20
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-articular administration
Trial: NCT04588727
Drug: AZD3366
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
Trial: NCT04588727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
Trial: NCT04588727
Drug: acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part B, subjects will receive oral ASA chewable tablets.
Trial: NCT00197444
Drug: CDGP/5-FU combined with radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
Trial: NCT01210144
Drug: Gonal -f® [r-hFSH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
Trial: NCT01210144
Drug: Ovitrelle® [r-hCG alfa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (\>) 16 millimeter (mm), and with estradiol (E2) \> 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
Trial: NCT01210144
Drug: Gonadotropin-releasing hormone (GnRH) Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
Trial: NCT00435019
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. injection, once or twice daily.
Trial: NCT00657306
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg/6 h per day
Trial: NCT00657306
Drug: dextrose solution 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextrose solution 5% 100 ml/6 h per day
Trial: NCT03462459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
Trial: NCT00403845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Trial: NCT01465633
Drug: levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03053427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01557322
Drug: methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
Trial: NCT04531163
Drug: N Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
Trial: NCT01359267
Drug: 99mTc-EC-DG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
Trial: NCT02071082
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Trial: NCT00865943
Drug: CELEXATM 10 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
Trial: NCT02334176
Drug: lidocaine 1.5% with epinephrine 5µg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
Trial: NCT00431873
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD0103 Administered orally three times per week.
Trial: NCT02404389
Drug: Investigational Treatment
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
Trial: NCT00925821
Drug: RAD
RxNorm normalized name: Durad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
Trial: NCT00576732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution qd or bid for 6 weeks
Trial: NCT03219008
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
Trial: NCT04305002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections, once weekly for 18 months
Trial: NCT03339336
Drug: BIIB074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03339336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02101359
Drug: Mydriatics
RxNorm normalized name: prednisolone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
Trial: NCT02465996
Drug: Puyuanhewei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
Trial: NCT00756600
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
Trial: NCT04620954
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m\^2 and 5 AUC (Area Under the Curve) respectively.
Trial: NCT01330953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous placebo dose.
Trial: NCT01330953
Drug: LY2928057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose.
Trial: NCT02547974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
Trial: NCT00874562
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
Trial: NCT03040427
Drug: F-18 florbetapir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
Trial: NCT02577367
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administer Levothyroxine
Trial: NCT02109172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02899533
Drug: [18F] FES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\] FES PET/CT scan, imaging tracer
Trial: NCT01667367
Drug: RG1662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT01667367
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT00226512
Drug: Campath-1H /ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02094521
Drug: NNC0113-0987
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
Trial: NCT02826525
Drug: AZD4076
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product
Trial: NCT02826525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control